Annual Total Expenses
$491.68 M
+$99.09 M+25.24%
31 December 2023
Summary:
Halozyme Therapeutics annual total expenses is currently $491.68 million, with the most recent change of +$99.09 million (+25.24%) on 31 December 2023. During the last 3 years, it has risen by +$324.27 million (+193.70%). HALO annual total expenses is now at all-time high.HALO Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Expenses
$126.89 M
+$12.77 M+11.19%
30 September 2024
Summary:
Halozyme Therapeutics quarterly total expenses is currently $126.89 million, with the most recent change of +$12.77 million (+11.19%) on 30 September 2024. Over the past year, it has dropped by -$2.12 million (-1.64%). HALO quarterly total expenses is now -1.64% below its all-time high of $129.00 million, reached on 31 December 2023.HALO Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HALO Total Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -1.6% |
| 3 y3 years | +193.7% | +179.1% |
| 5 y5 years | +86.5% | +48.0% |
HALO Total Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +298.6% | -1.6% | +215.3% |
| 5 y | 5 years | at high | +298.6% | -1.6% | +407.2% |
| alltime | all time | at high | -1.6% | >+9999.0% |
Halozyme Therapeutics Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $126.89 M(+11.2%) |
| June 2024 | - | $114.12 M(+13.7%) |
| Mar 2024 | - | $100.34 M(-22.2%) |
| Dec 2023 | $491.68 M(+25.2%) | $129.00 M(+1.0%) |
| Sept 2023 | - | $127.75 M(+0.9%) |
| June 2023 | - | $126.58 M(+16.8%) |
| Mar 2023 | - | $108.34 M(+1.3%) |
| Dec 2022 | $392.58 M(+134.5%) | $106.99 M(-14.9%) |
| Sept 2022 | - | $125.68 M(+6.2%) |
| June 2022 | - | $118.31 M(+184.3%) |
| Mar 2022 | - | $41.61 M(-8.5%) |
| Dec 2021 | $167.41 M(+35.7%) | $45.47 M(+13.0%) |
| Sept 2021 | - | $40.24 M(-7.3%) |
| June 2021 | - | $43.41 M(+13.4%) |
| Mar 2021 | - | $38.29 M(-13.1%) |
| Dec 2020 | $123.34 M(-53.2%) | $44.08 M(+76.2%) |
| Sept 2020 | - | $25.02 M(-2.5%) |
| June 2020 | - | $25.67 M(-10.2%) |
| Mar 2020 | - | $28.58 M(-66.7%) |
| Dec 2019 | $263.60 M(+19.2%) | $85.73 M(+21.1%) |
| Sept 2019 | - | $70.77 M(+33.2%) |
| June 2019 | - | $53.13 M(-1.6%) |
| Mar 2019 | - | $53.98 M(-10.5%) |
| Dec 2018 | $221.19 M(-6.1%) | $60.30 M(+18.2%) |
| Sept 2018 | - | $51.03 M(-7.7%) |
| June 2018 | - | $55.27 M(+1.3%) |
| Mar 2018 | - | $54.58 M(-14.2%) |
| Dec 2017 | $235.61 M(+2.5%) | $63.63 M(+14.3%) |
| Sept 2017 | - | $55.65 M(-6.0%) |
| June 2017 | - | $59.23 M(+3.7%) |
| Mar 2017 | - | $57.09 M(-7.3%) |
| Dec 2016 | $229.90 M(+41.5%) | $61.58 M(+12.8%) |
| Sept 2016 | - | $54.60 M(-0.8%) |
| June 2016 | - | $55.06 M(-6.2%) |
| Mar 2016 | - | $58.67 M(+25.5%) |
| Dec 2015 | $162.51 M(+17.4%) | $46.76 M(+6.2%) |
| Sept 2015 | - | $44.02 M(+12.4%) |
| June 2015 | - | $39.15 M(+20.2%) |
| Mar 2015 | - | $32.58 M(-4.8%) |
| Dec 2014 | $138.37 M(+2.3%) | $34.23 M(+1.8%) |
| Sept 2014 | - | $33.63 M(+0.9%) |
| June 2014 | - | $33.33 M(-10.4%) |
| Mar 2014 | - | $37.19 M(+9.9%) |
| Dec 2013 | $135.23 M | $33.82 M(-2.0%) |
| Sept 2013 | - | $34.51 M(-5.7%) |
| June 2013 | - | $36.58 M(+20.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2013 | - | $30.33 M(+15.8%) |
| Dec 2012 | $95.95 M(+26.4%) | $26.20 M(+3.3%) |
| Sept 2012 | - | $25.36 M(+16.3%) |
| June 2012 | - | $21.81 M(-3.4%) |
| Mar 2012 | - | $22.58 M(+8.4%) |
| Dec 2011 | $75.93 M(+11.8%) | $20.84 M(+17.1%) |
| Sept 2011 | - | $17.79 M(-11.5%) |
| June 2011 | - | $20.09 M(+16.8%) |
| Mar 2011 | - | $17.20 M(-19.8%) |
| Dec 2010 | $67.88 M(-5.9%) | $21.46 M(+35.5%) |
| Sept 2010 | - | $15.83 M(+3.0%) |
| June 2010 | - | $15.37 M(+0.9%) |
| Mar 2010 | - | $15.23 M(-20.3%) |
| Dec 2009 | $72.13 M(+21.8%) | $19.12 M(+12.7%) |
| Sept 2009 | - | $16.97 M(-8.3%) |
| June 2009 | - | $18.51 M(+5.6%) |
| Mar 2009 | - | $17.53 M(-12.7%) |
| Dec 2008 | $59.20 M(+85.3%) | $20.09 M(+47.0%) |
| Sept 2008 | - | $13.66 M(+6.7%) |
| June 2008 | - | $12.81 M(+1.3%) |
| Mar 2008 | - | $12.64 M(+12.2%) |
| Dec 2007 | $31.95 M(+92.9%) | $11.27 M(+21.8%) |
| Sept 2007 | - | $9.25 M(+41.4%) |
| June 2007 | - | $6.54 M(+33.8%) |
| Mar 2007 | - | $4.89 M(-4.0%) |
| Dec 2006 | $16.56 M(+21.0%) | $5.10 M(+21.6%) |
| Sept 2006 | - | $4.19 M(+18.5%) |
| June 2006 | - | $3.53 M(-5.7%) |
| Mar 2006 | - | $3.75 M(+3.1%) |
| Dec 2005 | $13.69 M(+50.6%) | $3.63 M(-4.1%) |
| Sept 2005 | - | $3.79 M(+26.7%) |
| June 2005 | - | $2.99 M(-8.5%) |
| Mar 2005 | - | $3.27 M(+29.4%) |
| Dec 2004 | $9.09 M(>+9900.0%) | $2.53 M(-22.5%) |
| Sept 2004 | - | $3.26 M(+56.2%) |
| June 2004 | - | $2.09 M(+73.0%) |
| Mar 2004 | - | $1.21 M(-217.0%) |
| Dec 2003 | $0.00(0.0%) | -$1.03 M(-352.9%) |
| Sept 2003 | - | $408.20 K(+9.5%) |
| June 2003 | - | $372.90 K(+48.3%) |
| Mar 2003 | - | $251.40 K(-449.2%) |
| Dec 2002 | $0.00(-100.0%) | -$72.00 K(-344.9%) |
| Sept 2002 | - | $29.40 K(+12.6%) |
| June 2002 | - | $26.10 K(+58.2%) |
| Mar 2002 | - | $16.50 K |
| Dec 2001 | $64.40 K | - |
FAQ
- What is Halozyme Therapeutics annual total expenses?
- What is the all time high annual total expenses for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly total expenses?
- What is the all time high quarterly total expenses for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly total expenses year-on-year change?
What is Halozyme Therapeutics annual total expenses?
The current annual total expenses of HALO is $491.68 M
What is the all time high annual total expenses for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual total expenses is $491.68 M
What is Halozyme Therapeutics quarterly total expenses?
The current quarterly total expenses of HALO is $126.89 M
What is the all time high quarterly total expenses for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly total expenses is $129.00 M
What is Halozyme Therapeutics quarterly total expenses year-on-year change?
Over the past year, HALO quarterly total expenses has changed by -$2.12 M (-1.64%)